219 related articles for article (PubMed ID: 25795705)
1. TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.
Geng D; Kaczanowska S; Tsai A; Younger K; Ochoa A; Rapoport AP; Ostrand-Rosenberg S; Davila E
Cancer Res; 2015 May; 75(10):1959-1971. PubMed ID: 25795705
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
3. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
[TBL] [Abstract][Full Text] [Related]
4. Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens.
Geng D; Zheng L; Srivastava R; Velasco-Gonzalez C; Riker A; Markovic SN; Davila E
Cancer Res; 2010 Oct; 70(19):7442-54. PubMed ID: 20807806
[TBL] [Abstract][Full Text] [Related]
5. Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.
de Melo FM; Braga CJ; Pereira FV; Maricato JT; Origassa CS; Souza MF; Melo AC; Silva P; Tomaz SL; Gimenes KP; Scutti JA; Juliano MA; Zamboni DS; Câmara NO; Travassos LR; Ferreira LC; Rodrigues EG
Immunol Cell Biol; 2015 Jan; 93(1):86-98. PubMed ID: 25223833
[TBL] [Abstract][Full Text] [Related]
6. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.
Ankri C; Shamalov K; Horovitz-Fried M; Mauer S; Cohen CJ
J Immunol; 2013 Oct; 191(8):4121-9. PubMed ID: 24026081
[TBL] [Abstract][Full Text] [Related]
7. Ameliorating the tumor microenvironment for antitumor responses through TLR5 ligand-secreting T cells.
Kaczanowska S; Davila E
Oncoimmunology; 2016 Apr; 5(4):e1076609. PubMed ID: 27141375
[TBL] [Abstract][Full Text] [Related]
8. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
9. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses.
Garaude J; Kent A; van Rooijen N; Blander JM
Sci Transl Med; 2012 Feb; 4(120):120ra16. PubMed ID: 22323829
[TBL] [Abstract][Full Text] [Related]
11. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
[TBL] [Abstract][Full Text] [Related]
12. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
13. Two-step enhanced cancer immunotherapy with engineered
Zheng JH; Nguyen VH; Jiang SN; Park SH; Tan W; Hong SH; Shin MG; Chung IJ; Hong Y; Bom HS; Choy HE; Lee SE; Rhee JH; Min JJ
Sci Transl Med; 2017 Feb; 9(376):. PubMed ID: 28179508
[TBL] [Abstract][Full Text] [Related]
14. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
15. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice.
Amos SM; Pegram HJ; Westwood JA; John LB; Devaud C; Clarke CJ; Restifo NP; Smyth MJ; Darcy PK; Kershaw MH
Cancer Immunol Immunother; 2011 May; 60(5):671-83. PubMed ID: 21327636
[TBL] [Abstract][Full Text] [Related]
17. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
18. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.
Iannone R; Miele L; Maiolino P; Pinto A; Morello S
Neoplasia; 2013 Dec; 15(12):1400-9. PubMed ID: 24403862
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.
Chinnasamy D; Tran E; Yu Z; Morgan RA; Restifo NP; Rosenberg SA
Cancer Res; 2013 Jun; 73(11):3371-80. PubMed ID: 23633494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
